EXEL catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on EXEL PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| 1H 2025Half-year disclosed | zanzalintinib (XL092) | EXEL | Interim readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| 1H 2025Half-year disclosed | zanzalintinib (XL092) | EXEL | Trial start | advanced NET, regardless of site of origin | Scheduled | SEC 8-K Exhibit 99.1 |
| Aug 2024Month disclosed | CABOMETYX® (cabozantinib) | EXEL | NDA/BLA accepted | — | Completed | SEC Form 10-K |
| Aug 2023Month disclosed | CABOMETYX® (cabozantinib) | EXEL | Topline readout | measurable, extra-pelvic metastatic castration-resistant prostate cancer | Positive | SEC Form 10-Q |
| July 14, 2022 | Cabometyx (cabozantinib s-malate) | EXEL | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 17, 2021 | Cabometyx (cabozantinib s-malate) | EXEL | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 22, 2021 | Cabometyx (cabozantinib s-malate) | EXEL | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 25, 2016 | Cabometyx (cabozantinib s-malate) | EXEL | FDA approval | — | Approved | openFDA Drugs@FDA |
Every catalyst is quoted from EXEL’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.